New Tumor Protein Mapping Platform characterizes functional tumor biology across four critical dimensions

Sapient's platform includes SurfaceSeek™ to identify druggable tumor cell surface proteins, SignalingSeek™ to measure signaling pathway activation, and ImmuneSeek™ and ResistanceSeek™ to map immune and resistance biology – directly in fresh-frozen and FFPE human tumors.

By directly mapping this dynamic tumor biology at the protein level, we give R&D teams a comprehensive view of what is actually governing therapeutic outcomes – moving oncology development beyond genomic inference alone.

Discovery of hypoxanthine as an early predictor of hypoxic‑ischemic encephalopathy severity

Publication: Explore the findings from this study published in Pediatric Research, led by UCSF investigators and for which Sapient provided discovery metabolomics.

Functional Tumor Biology Can’t Be Inferred, But It Can Be Measured.

Article: See why the discrepancy between what the genome predicts & what proteins actually do is one of the most consistent reasons oncology programs fail – and how modern tumor proteomics closes this gap.

Multi-Omics Exosome Profiling Reveals Potential Targets for Attenuating Diabetic Pathophysiology

Case Study: See how proteomics, metabolomics, and lipidomics were applied in a study by GATC Health to identify distinct multi-omic signatures in stem cell–derived exosomes that may protect insulin-producing cells from damage in diabetes.

Proteomics Atlas of Normal Human Tissue Biology to De-risk Target Selection

White Sheet: Explore how the DynamiQ™ Normal Human Tissue Proteomics Atlas provides a reference map of normal human tissue biology through multi-dimensional proteomic characterization across the primary organs associated with dose-limiting toxicities. 

Discover the value of protein-level measurements for direct evidence of dynamic functional tumor biology

Thursday, July 23, 2026 | 11:30am ET / 8:30am PT

Explore advancements that have made the functional proteome accessible at scale in human tumors, across the dimensions that determine whether a drug will be effective in the patient tumor – including real-world examples of novel targets and biology uncovered using mass spectrometry-based proteomics. 

How can protein mapping transform target discovery in precision oncology?

Dr. Jeramie Watrous, Co-Founder and Head of Research & Development at Sapient, recently spoke with Technology Networks about the evolving landscape of tumor protein mapping and what it means for oncology research. Click to see the feature.

FFPE Proteomics Draws a Crowd at ASMS 2026

Thank you to everyone who attended Sapient's ASMS poster session detailing our next-generation FFPE proteomics method. It is clear from the large crowds that gathered all day that R&D teams are seeing this as a true 'unlock' for discovery of novel targets & biomarkers in their existing archived samples.

If you couldn't make our session, we'd be happy to share a digital version of our poster. Reach out here.

Liquid Biopsy for Precision Oncology Summit

July 20 – 22

Boston, MA

Learn how we can extract thousands of molecular features – proteins, metabolites, cytokines – from a single plasma sample.

Targeted RLT Summit US

July 21 – 23

Boston, MA

We will be showcasing how SurfaceSeek™ identifies druggable tumor cell surface proteins and characterizes them as ideal targets for radioligand therapies.

Ready to discover more?

10421 Wateridge Circle, Suite 100
San Diego, CA 92121

858.290.7010

©2026 Sapient Bioanalytics, LLC. All rights reserved.